Coalition submits formal comment on FDA Draft Guidance on “Presenting Risk Information in Prescription Drug and Medical Device Promotion”.
The coalition’s comment, which commends the draft’s many strong points, also criticizes what they believe is the FDA’s over complication of advertising and promotion.
Read the full comment
FDA Draft Guidance: Coalition Submits Formal Comment
Coalition submits formal comment on FDA Draft Guidance on “Presenting Risk Information in Prescription Drug and Medical Device Promotion”.
The coalition’s comment, which commends the draft’s many strong points, also criticizes what they believe is the FDA’s over complication of advertising and promotion.
Read the full comment
Related Posts
Plausible Options for a FDA Rulemaking on Rx Adverting
The Rise of DTP Rx Discount Platforms
Legal Group to FDA: Pursue Drug Ad Restrictions, Receive Constitutional Challenge